CM 2395Alternative Names: CM-2,395
Latest Information Update: 27 Oct 2009
At a glance
- Originator Cenomed BioSciences
- Class Antipsychotics
- Mechanism of Action Adrenergic receptor antagonists; Dopamine D2 receptor agonists; Serotonin 1B receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Schizophrenia
Most Recent Events
- 27 Oct 2009 Clinical trials in Schizophrenia in USA (PO)